IL2 and neoplasm: To further improve treatment response, in the same study (NCT01132014), the combination of HOCl-oxidised autologous whole-tumor lysate-pulsed moDC vaccine, bevacizumab/cyclophosphamide, acetylsalicylic acid (ASA,) and IL-2 was assessed.